Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding AG    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
  • In a short-term perspective, the company has interesting fundamentals.
Strengths
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Weaknesses
  • Stock prices approach a strong long-term resistance in weekly data at CHF 345.8.
  • The group usually releases earnings worse than estimated.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
ROCHE HOLDING AG2.77%277 060
JOHNSON & JOHNSON-8.02%345 705
MERCK & CO., INC-16.16%195 141
NOVARTIS-11.15%187 703
PFIZER, INC.-14.14%181 075
NOVO NORDISK A/S7.93%141 503
BRISTOL-MYERS SQUIBB COMPAN..-13.49%126 110
ELI LILLY AND COMPANY6.26%125 824
AMGEN INC.-14.79%119 572
ASTRAZENECA PLC-6.09%117 896
ABBVIE INC.-17.13%112 508
SANOFI-9.22%110 172
GLAXOSMITHKLINE-16.28%93 854
CHUGAI PHARMACEUTICAL CO., ..0.77%63 605
ALLERGAN PLC-8.09%58 266
JIANGSU HENGRUI MEDICINE CO..0.00%57 229
More Results
Financials (CHF)
Sales 2020 62 475 M
EBIT 2020 23 274 M
Net income 2020 15 038 M
Finance 2020 3 051 M
Yield 2020 2,91%
P/E ratio 2020 18,4x
P/E ratio 2021 17,4x
EV / Sales2020 4,34x
EV / Sales2021 4,11x
Capitalization 274 B
Upcoming event on ROCHE HOLDING AG
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes